A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Rezafungin (Primary)
  • Indications Candidiasis; Vulvovaginal candidiasis
  • Focus Adverse reactions
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 06 Dec 2016 Results of PK-pharmacodynamic data analysis from two phase I dose-escalation studies (NCT02516904 and NCT02551549), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 Safety results from two phase I, dose-escalation studies (NCT02516904 and NCT02551549), published in the Antimicrobial Agents and Chemotherapy
    • 28 Nov 2016 According to a Cidara Therapeutics media release, data from this trial will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top